Falecalcitriol

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326765

CAS#: 83805-11-2

Description: Falecalcitriol is an analog of calcitriol. It has a higher potency both in vivo and in vitro systems, and longer duration of action in vivo. Falecalcitriol may be potentially used for conventional vitamin D therapy-resistant secondary hyperparathyroidism in a continuous ambulatory peritoneal dialysis patient.


Chemical Structure

img
Falecalcitriol
CAS# 83805-11-2

Theoretical Analysis

MedKoo Cat#: 326765
Name: Falecalcitriol
CAS#: 83805-11-2
Chemical Formula: C27H38F6O3
Exact Mass: 524.2725
Molecular Weight: 524.5884
Elemental Analysis: C, 61.82; H, 7.30; F, 21.73; O, 9.15

Price and Availability

Size Price Availability Quantity
1.0mg USD 1450.0 2 Weeks
Bulk inquiry

Synonym: Ro 23-4194; Ro-23-4194; Ro23-4194; ST 630; ST-630; ST630; Flocalcitriol; Hornel, Fulstan; Falecalcitriol.

IUPAC/Chemical Name: (1S,3R,Z)-5-(2-((1R,3aS,7aR,E)-7a-methyl-1-((R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl)octahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol

InChi Key: XPYGGHVSFMUHLH-PSEHTZQNSA-N

InChi Code: InChI=1S/C27H38F6O3/c1-16(6-4-13-25(36,26(28,29)30)27(31,32)33)21-10-11-22-18(7-5-12-24(21,22)3)8-9-19-14-20(34)15-23(35)17(19)2/h8-9,16,20-23,34-36H,2,4-7,10-15H2,1,3H3/b18-8+,19-9-/t16-,20+,21-,22+,23-,24-/m1/s1

SMILES Code: C[C@H](CCCC(C(F)(F)F)(O)C(F)(F)F)[C@H]([C@]1(CCC/2)C)CC[C@@]1([H])C2=C\C=C3C[C@H](O)C[C@@H](O)C\3=C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 524.5884 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ito H, Ogata H, Yamamoto M, Takahashi K, Shishido K, Takahashi J, Taguchi S, Kinugasa E. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial. Clin Nephrol. 2009 Jun;71(6):660-8. PubMed PMID: 19473635.

2: Tokunaga M, Tamura M, Kabashima N, Serino R, Shibata T, Matsumoto M, Miyamoto T, Miyazaki M, Furuno Y, Takeuchi M, Abe H, Okazaki M, Otsuji Y. Falecalcitriol for conventional vitamin D therapy-resistant secondary hyperparathyroidism in a continuous ambulatory peritoneal dialysis patient. Clin Nephrol. 2008 May;69(5):393-4. PubMed PMID: 18538106.

3: Iwao Y, Yamaguchi Y, Fujii K, Toba Y, Asada M, Nagano N, Yamamoto H, Hyoma K, Yamada S, Hirano H, Tone Y, Ohtani H, Saika Y, Fujii R. [Long-term suppressive effect of falecalcitriol on parathyroid hormone secretion in secondary hyperparathyroidism in hemodialysis patients]. Clin Calcium. 2006 May;16(5):847-51. Japanese. PubMed PMID: 16679628.

4: Morii H. [Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidism]. Clin Calcium. 2005 Jan;15(1):29-33. Review. Japanese. PubMed PMID: 15632470.

5: Ohtsuka N, Urayama K. [Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3]. Nihon Yakurigaku Zasshi. 2002 Dec;120(6):427-36. Review. Japanese. PubMed PMID: 12528474.

6: Komuro S, Sato M, Kanamaru H, Kaneko H, Nakatsuka I, Yoshitake A. In vivo and in vitro pharmacokinetics and metabolism studies of 26,26,26,27,27,27-F6-1,25(OH)2 vitamin D3 (Falecalcitriol) in rat: induction of vitamin D3-24-hydroxylase (CYP24) responsible for 23S-hydroxylation in target tissues and the drop in serum levels. Xenobiotica. 1999 Jun;29(6):603-13. PubMed PMID: 10426559.

7: Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1998 Aug;32(2):238-46. PubMed PMID: 9708607.